The deal priced at below last closing price of $18.92. Jefferies, TD Securities, Leerink, Stifel and Wedbush are acting as joint book running managers for the offering.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics announces common stock offering, no amount given
- Spyre Therapeutics announces poster presentations at UEGW 2025
- Spyre Therapeutics initiated with a Buy at Deutsche Bank
- Promising Developments and Strategic Trials Drive Buy Rating for Spyre Therapeutics
- Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial